Cargando…

Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs

The advent of directly acting antivirals (DAA) has determined a showy change in the management of hepatitis C virus (HCV) infection, the most common cause of hepatocellular carcinoma (HCC) in many countries. It was demonstrated that the achievement of sustained virologic response (SVR) with interfer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serio, Ilaria, Napoli, Lucia, Leoni, Simona, Piscaglia, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798330/ https://www.ncbi.nlm.nih.gov/pubmed/35117103 http://dx.doi.org/10.21037/tcr.2019.04.01

Ejemplares similares

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents
por: Sanduzzi-Zamparelli, Marco, et al.
Publicado: (2019)

Hypoglycemia, Fact or Fad
por: Greenbaum, Laurence
Publicado: (1984)

Fad, Fact and Fancy in Medicine
por: King, Clarence
Publicado: (1900)

Fad Diets: Facts and Fiction
por: Tahreem, Aaiza, et al.
Publicado: (2022)

Cardiac Toxicity Associated with HCV Direct Antiviral Agents
por: Ucciferri, Claudio, et al.
Publicado: (2018)

Porcelain: A Fad or a Fact
por: Ross, James
Publicado: (1903)

Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
por: Dash, Srikanta, et al.
Publicado: (2020)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents
por: Yoo, Hae Won, et al.
Publicado: (2022)

Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
por: Dias, Cátia, et al.
Publicado: (2018)

The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence
por: Cavalletto, Luisa, et al.
Publicado: (2023)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Internet addiction disorder: Fact or Fad? Nosing into Nosology
por: Swaminath, G.
Publicado: (2008)

Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
por: Usmani, Saad Z.
Publicado: (2012)

Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma
por: Giovannini, Catia, et al.
Publicado: (2020)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals
por: D’Ambrosio, Roberta, et al.
Publicado: (2021)

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
por: Rinaldi, Luca, et al.
Publicado: (2020)

Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals
por: Vernuccio, Federica, et al.
Publicado: (2022)

Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy
por: Fatima, Tehreem, et al.
Publicado: (2020)

Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis
por: Leoni, Simona, et al.
Publicado: (2018)

Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents
por: Ali, Mohamed E., et al.
Publicado: (2021)

Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals
por: El-Kassas, Mohamed, et al.
Publicado: (2023)

Direct anti-HCV agents
por: Zhang, Xingquan
Publicado: (2016)

Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues
por: Tampaki, Maria, et al.
Publicado: (2018)

Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents
por: Mathur, Karan, et al.
Publicado: (2021)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2022)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
por: Abu-Freha, Naim, et al.
Publicado: (2023)

B-cell Clonality in HCV-Induced Patients Treated with Oral Direct-Acting Antiviral Agents
por: Waly, Basma, et al.
Publicado: (2023)

Hepatocellular carcinoma with a direct right atrial extension in an HCV patient previously treated with direct-acting antiviral therapy: a case report
por: Abdelnabi, Mahmoud, et al.
Publicado: (2019)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
por: Pinchera, Biagio, et al.
Publicado: (2023)

Treatment of Combined Hepatocellular and Cholangiocarcinoma
por: Leoni, Simona, et al.
Publicado: (2020)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
por: Kawagishi, Naoki, et al.
Publicado: (2018)

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
por: Chen, Zhi-wei, et al.
Publicado: (2016)

The Truth About Leadership: The No-Fads, Heart-of-the-Matter Facts you Need to Know
por: Kouzes, James
Publicado: (2010)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_02p3bbhrg0sg1qa88n717grrb5